AKT1 and acute myeloid leukemia: For example, the evaluated response of 80 samples of primary AML samples to selective inhibitors of the PI3K/AKT/mTOR confirmed that ~60% of them display the pathway hyperactivation, which possibly also segregates with shortened OS [27].